SAM Chun Dang Pharm: Thin Profits and Very High Multiples After a Sharp One-Month Share Rise

Thesis

The data supports a picture of steady revenue growth and a return to modest profit. Revenue rose every year from 2022 to 2025, and the trailing operating margin of 6.8% is above the 3.7% reported for 2025. The data does not show what is driving the market value, which is far above what current earnings alone would imply. The trailing P/E is 280.3 and the EV/EBITDA is 182.2. The share price is 82.7% below its 52-week high of ₩1,233,000 and 77.1% above its 52-week low of ₩120,000, so the price has been very volatile. Investor flows, foreign ownership, short balance and news headlines are not available in the data, so we cannot say who is buying or selling. Several amended filings in October, including amended half-year and quarterly reports, are visible, but their content is not described in the data.

Business overview

SAM Chun Dang Pharm is listed on KOSDAQ in the Biotech & Pharma sector. It was founded on 1943-12-29 and listed on 2000-10-04, with 23,457,472 listed shares. The CEO is listed as 전인석. Revenue grew from ₩167.3B in 2021 to ₩231.8B in 2025, with growth of 6.0% in 2022, 8.6% in 2023, 9.5% in 2024 and 9.9% in 2025. Trailing revenue as of H1 2026 is ₩259.9B. The data does not describe products or the pipeline.

Financial analysis

These figures come from filed financial statements (DART). Trailing revenue is ₩259.9B, operating income ₩17.7B and net income ₩17.8B, giving operating and net margins of 6.8% each. ROE is 6.3%. In 2025, operating income was ₩8.5B (3.7% margin) and net income ₩5.3B (ROE 1.9%). Net losses occurred in 2021 (₩16.6B), 2023 (₩10.4B) and 2024 (₩10.9B), so earnings have been uneven. On the balance sheet, liabilities to equity is 43.6%, cash is ₩63.0B and borrowings are ₩26.0B. Trailing free cash flow is negative at ₩30.6B, meaning the company spent more than its operations generated.

Valuation

Current multiples are P/E 280.3, P/B 16.5, P/S 19.2 and EV/EBITDA 182.2, with a dividend yield of 0.0%. Enterprise value is about ₩4.9T. At the end of 2025 the P/E was 1,036.5 and the P/B 19.8, so multiples are lower than then but remain high; earlier year-end multiples are not available. Among listed peers, P/E is 43.1 for Samsung Biologics, 26.4 for Celltrion, 64.1 for Alteogen and 28.0 for Hanmi Pharm (HLB's is not available). Peer P/B is 10.2, 2.3, 23.1, 4.3 and 17.0 respectively. SAM Chun Dang's P/E is well above all peers shown, and its P/B is higher than most, though below Alteogen's.

Catalysts

• Amended half-year (Jun 2026) and quarterly (Mar 2026) reports were filed on 2026-10-08, and investors may look at what changed.
• An amended filing on a major management matter relevant to investors was made on 2026-10-01, though its details are not in the data.
• The 5%+ holding reports filed on 2026-07-23 and 2026-08-14 point to changes in large shareholdings.
• An extraordinary shareholders' meeting result and an independent director filing were made on 2026-06-30.
• The next financial statements will show whether the trailing margin of 6.8% holds.

Risks

• The trailing P/E of 280.3 leaves little room in earnings if profit growth disappoints.
• Trailing free cash flow is negative at ₩30.6B, which could increase reliance on cash reserves or borrowing.
• Profit history is uneven, with net losses in three of the last five years.
• The share price rose 32.2% in one month and sits far below its 52-week high, showing large price swings.
• Investor flows, foreign ownership, short interest and news are not available, so market positioning cannot be assessed.

Closing view

The filed numbers show a company with steadily growing revenue and a recent recovery to modest profitability, but earnings remain small relative to a market value of about ₩5.0T. Multiples are far above those of the peers shown and the company's free cash flow is negative. Amended filings add some uncertainty, as their content is not in the data. The evidence points to a valuation that relies heavily on expectations that the data cannot confirm.

Model estimate of fair value

The valuation model has no estimate for this company yet (not enough data, or no positive value with the base case).

Report history

1. Oct 13, 2026InitiationSAM Chun Dang Pharm: Thin Profits and Very High Multiples After a Sharp One-Month Share Rise